BHIC's Revenue Soars 233%, But Quarterly Loss Raises 'Going Concern' Flag

TL;DR

**BHIC's nine-month numbers look great, but that Q3 loss and 'going concern' warning mean this stock is a high-risk gamble on future funding.**

AI Summary

BioScience Health Innovations, Inc. (BHIC) reported a significant increase in revenue and net income for the nine months ended September 30, 2025. Revenue surged to $4,115,960, a substantial increase from $1,234,744 in the prior year, representing a 233% growth. Net income for the nine-month period reached $875,720, a dramatic improvement from $77,043 in the same period of 2024. However, the company experienced a net loss of $8,782 for the three months ended September 30, 2025, compared to a net income of $56,202 in the corresponding 2024 quarter. Cash and cash equivalents increased to $1,139,423 as of September 30, 2025, up from $662,517 at December 31, 2024. Inventory also saw a substantial rise to $757,500 from $58,319. The company changed its name from Nowtransit Inc. to BioScience Health Innovations Inc. on February 21, 2025, and is actively pursuing multiple patent applications for its methylithioninium (methylene blue) and mitochondrial health compositions, incurring $72,101 in patent application costs. Despite current profitability, the company acknowledges a 'going concern' risk due to past losses and reliance on related party advances, planning to raise additional funds through private or public offerings.

Why It Matters

BHIC's impressive 233% revenue growth and significant net income for the nine-month period signal strong operational momentum in the health and wellness sector, potentially attracting growth-oriented investors. However, the Q3 2025 net loss and the explicit 'going concern' disclosure, citing past losses and reliance on related party financing, introduce considerable risk. This mixed performance could deter cautious investors, while employees might face uncertainty regarding long-term stability if additional funding isn't secured. For customers, the company's focus on innovative products like methylithioninium compositions suggests a commitment to new health solutions, but the financial instability could impact future product development or availability. In a competitive market, BHIC's ability to secure external funding and maintain profitability will be crucial for its survival and market positioning against established health supplement companies.

Risk Assessment

Risk Level: high — The company explicitly states a 'going concern' risk due to past losses and reliance on advances from related parties, despite current profitability. As of September 30, 2025, BHIC had $638,960 in cash balances exceeding FDIC insurance limits at Wells Fargo Bank, indicating potential uninsured risk. The company's ability to continue is dependent on generating sufficient revenue and raising additional funds, with no assurances to that effect.

Analyst Insight

Investors should approach BHIC with extreme caution, recognizing the significant 'going concern' risk despite strong nine-month revenue growth. Await concrete evidence of successful capital raises or sustained quarterly profitability before considering an investment. Monitor future filings for updates on funding efforts and a consistent trend of positive net income.

Financial Highlights

debt To Equity

N/A

revenue

$4,115,960

operating Margin

N/A

total Assets

$2,067,100

total Debt

N/A

net Income

$875,720

eps

N/A

gross Margin

N/A

cash Position

$1,139,423

revenue Growth

+233%

Revenue Breakdown

Key Numbers

• $4,115,960 — Revenue for nine months ended Sep 30, 2025 (Increased 233% from $1,234,744 in 2024)
• $875,720 — Net Income for nine months ended Sep 30, 2025 (Significant improvement from $77,043 in 2024)
• $(8,782) — Net Loss for three months ended Sep 30, 2025 (Shift from $56,202 net income in Q3 2024)
• $1,139,423 — Cash and cash equivalents as of Sep 30, 2025 (Increased from $662,517 at Dec 31, 2024)
• $757,500 — Inventory as of Sep 30, 2025 (Substantial increase from $58,319 at Dec 31, 2024)
• $534,637 — Accumulated earnings as of Sep 30, 2025 (Shift from accumulated deficit of $(341,083) at Dec 31, 2024)
• $72,101 — Intangible assets (patent application costs) as of Sep 30, 2025 (Increased from $26,037 at Dec 31, 2024, reflecting patent investments)
• 10,979,055 — Common shares outstanding as of Oct 24, 2025 (Consistent with shares outstanding at Sep 30, 2025 and Dec 31, 2024)

Key Players & Entities

• BioScience Health Innovations, Inc. (company) — registrant
• BHIC (company) — ticker symbol
• Nowtransit Inc. (company) — former company name
• Best 365 Labs Inc. (company) — wholly owned subsidiary
• Wells Fargo Bank (company) — bank where cash is held
• Thorpe North and Western (company) — patent filing firm
• Securities and Exchange Commission (regulator) — filing oversight
• Nevada (regulator) — state of incorporation

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company acknowledges a 'going concern' risk due to historical losses and reliance on related party advances. Management plans to raise additional funds through private or public offerings to address this uncertainty.
• Reliance on Future Funding [high — financial]: The company's ability to continue as a going concern is dependent on its success in raising additional capital through future offerings. Failure to secure necessary funding could impact operations.
• Inventory Build-up [medium — operational]: Inventory has increased substantially from $58,319 to $757,500. While this may support future sales, it also ties up significant capital and carries risks of obsolescence or write-downs.
• Related Party Transactions [medium — financial]: The company has 'Due to related parties' of $228,298, indicating financial reliance on related entities. This could present conflicts of interest or financial risks if not managed properly.
• Patent Application Costs [low — regulatory]: The company is incurring costs of $72,101 for patent applications related to its core technologies. While strategic, these costs impact current expenses and require successful patent grants for future value.

Industry Context

The bioscience and health innovations sector is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory landscape. Companies in this space often rely on intellectual property protection, such as patents, to secure market position and competitive advantage. The industry is highly competitive, with both established players and emerging startups vying for market share and funding.

Regulatory Implications

BHIC's focus on patent applications places it within a heavily regulated industry. Successful patent grants are crucial for market exclusivity and future revenue generation. Investors should monitor the progress and outcome of these patent applications, as well as any evolving FDA or other health authority regulations relevant to the company's products.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-02-21: Company name change from Nowtransit Inc. to BioScience Health Innovations Inc. — Marks a strategic pivot and rebranding towards the bioscience and health sector, signaling a new direction for the company.
• 2025-09-30: Nine months ended September 30, 2025 — Period of significant revenue growth ($4,115,960) and net income ($875,720), indicating strong operational performance for the year-to-date.
• 2025-09-30: Three months ended September 30, 2025 — Period showed a net loss of $8,782, a reversal from the prior year's Q3 net income, highlighting recent quarterly volatility despite year-to-date profitability.
• 2025-09-30: Cash and cash equivalents reached $1,139,423 — A substantial increase from $662,517 at year-end 2024, improving liquidity and financial flexibility.
• 2025-09-30: Inventory increased to $757,500 — A significant rise from $58,319, suggesting increased production or stock for anticipated sales, but also a potential risk if demand does not materialize.
• 2024-12-31: Accumulated deficit of $(341,083) — The company has successfully transitioned to accumulated earnings of $534,637 by September 30, 2025, indicating a significant turnaround.

Glossary

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (BHIC explicitly states a 'going concern' risk, meaning investors need to be aware of potential financial instability and the need for future funding.)

Intangible Assets

Non-physical assets that have value, such as patents, trademarks, and copyrights. In this case, it represents costs associated with patent applications. (The increase in intangible assets to $72,101 reflects BHIC's investment in intellectual property for its bioscience innovations.)

Accumulated Earnings (Deficit)

The total net income or loss of a company over its entire history that has not been distributed to shareholders as dividends. (BHIC's shift from an accumulated deficit of $(341,083) to accumulated earnings of $534,637 signifies a major financial turnaround.)

Related Parties

Entities or individuals that have the ability to control or significantly influence the financial or operating decisions of another entity. Transactions between them require disclosure. (BHIC has 'Due to related parties' of $228,298, highlighting financial interdependencies that warrant investor scrutiny.)

Deferred Revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. It is recorded as a liability until earned. (The increase in deferred revenue to $110,991 suggests future revenue streams from services or products already paid for.)

Year-Over-Year Comparison

BioScience Health Innovations, Inc. has demonstrated a dramatic turnaround in its financial performance compared to the prior year. Revenue for the nine months ended September 30, 2025, surged by 233% to $4,115,960 from $1,234,744 in the same period of 2024. Net income also saw a significant improvement, reaching $875,720 compared to a modest $77,043 in the prior year. However, the most recent quarter (Q3 2025) showed a net loss of $8,782, a reversal from Q3 2024's net income, indicating some recent operational volatility. Cash reserves have strengthened considerably, and inventory has seen a substantial increase, reflecting significant strategic shifts and investments.

Key Financial Figures

• $0.0001 — (g) of the Act: Common stock, par value $0.0001 Indicate by check mark whether the re

Filing Documents

• bhic10q093025.htm (10-Q) — 338KB
• bhicex31-1.htm (EX-31.1) — 12KB
• bhicex31-2.htm (EX-31.2) — 12KB
• bhicex32-1.htm (EX-32.1) — 5KB
• bhicex32-2.htm (EX-32.2) — 4KB
• 0001185185-25-001545.txt ( ) — 2017KB
• bhic-20250930.xsd (EX-101.SCH) — 12KB
• bhic-20250930_cal.xml (EX-101.CAL) — 18KB
• bhic-20250930_def.xml (EX-101.DEF) — 72KB
• bhic-20250930_lab.xml (EX-101.LAB) — 140KB
• bhic-20250930_pre.xml (EX-101.PRE) — 82KB
• bhic10q093025_htm.xml (XML) — 126KB

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets (unaudited) 4 Condensed Consolidated Statements of Operations (unaudited) 5 Condensed Consolidated Statements of Stockholders ' Equity (Deficit) (unaudited) 6 Condensed Consolidated Statements of Cash Flows (unaudited) 7 Notes to Financial Consolidated Statements (unaudited) 8 Item 2 . Management ' s Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3 .

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4 .

Controls and Procedures

Controls and Procedures 19 PART II OTHER INFORMATION Item 1 .

Legal Proceedings

Legal Proceedings 20 Item 1A. Cybersecurity 20 Item 2 . Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3 . Defaults Upon Senior Securities 20 Item 4 . Mine Safety Disclosures 20 Item 5 . Other Information 20 Item 6 . Exhibits 21

Signatures

Signatures 22 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America ("US GAAP"). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company's December 31, 2024 audited financial statements and notes thereto. Operating results for the nine months ended September 30, 2025 are not necessarily indicative of the results that can be expected for the year ending December 31, 2025. 3 Table of Contents BIOSCIENCE HEALTH INNOVATIONS, INC (FORMERLY NOWTRANSIT INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 1,139,423 $ 662,517 Accounts receivable, net 63,212 100,285 Inventory 757,500 58,319 Prepaid expense 34,864 4,832 Overpayment to related parties - 21,798 Total current assets 1,994,999 847,751 Other Assets Intangible assets 72,101 26,037 Total Assets $ 2,067,100 $ 873,788 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable $ 10,165 $ 8,226 Due to related parties 228,298 - Accrued expenses 6,686 5,993 Deferred revenue 110,991 24,329 Total current liabilities 356,140 38,548 STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock: $0.0001 par value, 5,000,000 shares authorized;